Serobid

Serobid (Salmeterol Xinafoate) acts on the muscles of the airways, causing them to relax. This helps to open up the air passages, making breathing easier. It is indicated for the long term management and control of asthma, bronchitis, emphysema or other related breathing conditions. Treatment can help to prevent breathing difficulties and EIB (exercise induced bronchospasms). The active ingredient is classified as a long acting beta 2 agonist, and it can act directly on the lungs and cause the airways to open, with the effects lasting for up to 12 hours. However, it will not work quickly enough to provide relief from wheezing and other symptoms of a sudden asthma attack.

Serobid (Salmeterol Xinafoate) inhaler comes with 120 metered doses, and each actuation is able to deliver 25mcg of the active ingredient to the patient. Consult your physician so that the correct dosage can be carefully calculated. In general, this medicine is only used in combination with other forms of anti-inflammatory therapy for the management of asthma. Patients who are not currently undergoing any form of anti-inflammatory treatment will be instructed by their physician to do so. In some cases, adults may be directed to administer 2 puffs twice per day. Never exceed the dosage recommended by your physician.

Use of Serobid (Salmeterol Xinafoate) inhaler for breathing problems may cause side effects. Ensure that your physician is notified of any reactions that occur. Examples can include:

• Insomnia
• Vertigo and headaches
• Irritated throat or eyes
• Cramping of the muscles
• Nasal stuffiness or rhinitis

It will be necessary to cease the use of this inhaler and to get medical helps straight away if severe coughing, wheezing, pain in the chest, seizures, tremors or any other adverse events not referenced here occur.

Before you use Serobid (Salmeterol Xinafoate) inhaler, it may be necessary to prime the inhalation device by spraying 1 or 2 doses into the air. Also, ask your physician to instruction you on proper use.

There is a risk of paradoxical bronchospasm associated with this inhaler. This is characterized by a sudden and serious increase in wheezing after the administration of the medicine. You will require immediate hospital treatment if this happens.